Outcomes of Patients With Metastatic Non–Clear-Cell Renal Cell Carcinoma Treated With Pazopanib

Marc R. Matrana, Ali Baiomy, Matthew Campbell, Suhail Alamri, Aditya Shetty, Purnima Teegavarapu, Sarathi Kalra, Lianchun Xiao, Bradley Atkinson, Paul Corn, Eric Jonasch, Khaled M. Elsayes, Nizar M. Tannir

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Outcomes data in patients with metastatic non–clear-cell renal cell carcinoma (RCC) treated with pazopanib are limited. We identified 29 patients with non–clear-cell metastatic RCC who received pazopanib (9 in the front-line setting, and 20 in the salvage setting). Median overall survival was 31 months (95% confidence interval [CI], 9.2-NA [not available]) in the front-line group compared with 13.6 months (95% CI, 6.4-NA) in the salvage group. Background Pazopanib is associated with increased progression-free survival (PFS) in clear-cell renal cell carcinoma (RCC) and has become a standard of care in this disease. The drug is used in metastatic non–clear-cell RCC, but data on outcomes in this setting are limited. Patients and Methods We conducted a retrospective data analysis of records of consecutive metastatic non–clear-cell RCC patients who received pazopanib in front-line and salvage settings between November 2009 and November 2012. Tumor response rate was assessed by a blinded radiologist using Response Evaluation Criteria in Solid Tumors version 1.1. PFS and overall survival (OS) times were estimated using Kaplan–Meier methods. Results Twenty-nine patients were identified with non–clear-cell metastatic RCC, 9 received pazopanib in the front-line setting, 20 in the salvage setting after progression of disease with other targeted therapies. Seven patients (24%) had papillary RCC, 4 (14%) had chromophobe, 5 (17%) had unclassified histopathology, and 13 (45%) had other subtypes including collecting duct, translocation Xp11.2, and various subtypes with sarcomatoid differentiation. All patients discontinued pazopanib before analysis. Median PFS was 8.1 months (95% CI, 5.7-NA [not available]) in the front-line group, and 4 months (95% CI, 2.1-9.9) in the salvage group. Median OS was 31 months (95% CI, 9.2-NA) in the front-line group, and 13.6 months (95% CI, 6.4-NA) in the salvage group. Conclusion Pazopanib showed efficacy in patients with metastatic non–clear-cell RCC in the front-line and salvage settings. Toxicity was mild to moderate and manageable. Further studies are needed to evaluate pazopanib's role in non–clear-cell RCC in terms of efficacy and safety.

Original languageEnglish (US)
Pages (from-to)e205-e208
JournalClinical Genitourinary Cancer
Volume15
Issue number2
DOIs
StatePublished - Apr 1 2017

Keywords

  • Angiogenesis
  • Kidney cancer
  • Late relapse
  • Targeted therapy
  • Tyrosine-kinase inhibitor
  • mTOR inhibitor

ASJC Scopus subject areas

  • Oncology
  • Urology

MD Anderson CCSG core facilities

  • Biostatistics Resource Group

Fingerprint

Dive into the research topics of 'Outcomes of Patients With Metastatic Non–Clear-Cell Renal Cell Carcinoma Treated With Pazopanib'. Together they form a unique fingerprint.

Cite this